In addition to hyperlipidemia, low high-density lipoprotein cholesterol (HDL-C) levels are observed in metabolic syndrome and NAFLD, which could result from the combination of increased HDL-C clearance due to the activation of hepatic lipase (HL) and the impaired synthesis of HDL-C components such as apolipoprotein A-ǀ (ApoA-ǀ) [8]. Here, LIPC is linked to metabolic dysfunction-associated steatotic liver disease.